

Jiehua Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3395401/publications.pdf>

Version: 2024-02-01

36
papers

3,667
citations

218592

26
h-index

330025

37
g-index

38
all docs

38
docs citations

38
times ranked

5137
citing authors

#	ARTICLE	IF	CITATIONS
1	Aptamers as targeted therapeutics: current potential and challenges. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 181-202.	21.5	1,349
2	Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e169.	2.3	201
3	Adaptive Amphiphilic Dendrimer-Based Nanoassemblies as Robust and Versatile siRNA Delivery Systems. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 11822-11827.	7.2	181
4	Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. <i>Pharmaceuticals</i> , 2013, 6, 85-107.	1.7	171
5	Cell-Specific Aptamer-Mediated Targeted Drug Delivery. <i>Oligonucleotides</i> , 2011, 21, 1-10.	2.7	164
6	Systemic Administration of Combinatorial dsirRNAs via Nanoparticles Efficiently Suppresses HIV-1 Infection in Humanized Mice. <i>Molecular Therapy</i> , 2011, 19, 2228-2238.	3.7	149
7	Current Advances in Aptamers for Cancer Diagnosis and Therapy. <i>Cancers</i> , 2018, 10, 9.	1.7	139
8	Functional In Vivo Delivery of Multiplexed Anti-HIV-1 siRNAs via a Chemically Synthesized Aptamer With a Sticky Bridge. <i>Molecular Therapy</i> , 2013, 21, 192-200.	3.7	120
9	Aptamer-targeted cell-specific RNA interference. <i>Silence: A Journal of RNA Regulation</i> , 2010, 1, 4.	8.0	116
10	Current Progress of RNA Aptamer-Based Therapeutics. <i>Frontiers in Genetics</i> , 2012, 3, 234.	1.1	111
11	Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In Vivo Efficient Gene Silencing. <i>Small</i> , 2016, 12, 3667-3676.	5.2	78
12	Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 Inhibition. <i>Methods</i> , 2011, 54, 284-294.	1.9	77
13	Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. <i>Nucleic Acids Research</i> , 2013, 41, 4266-4283.	6.5	73
14	Cell-Specific RNA Aptamer against Human CCR5 Specifically Targets HIV-1 Susceptible Cells and Inhibits HIV-1 Infectivity. <i>Chemistry and Biology</i> , 2015, 22, 379-390.	6.2	71
15	Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. <i>Nature Communications</i> , 2016, 7, 10637.	5.8	67
16	High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency. <i>Scientific Reports</i> , 2016, 6, 33697.	1.6	66
17	Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics. <i>Biotechnology Advances</i> , 2014, 32, 844-852.	6.0	56
18	AptaTRACE Elucidates RNA Sequence-Structure Motifs from Selection Trends in HT-SELEX Experiments. <i>Cell Systems</i> , 2016, 3, 62-70.	2.9	55

#	ARTICLE	IF	CITATIONS
19	Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. <i>Theranostics</i> , 2018, 8, 1575-1590.	4.6	47
20	HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. <i>Journal of Virology</i> , 2018, 92, .	1.5	36
21	Dual Mechanisms of Action of Self-Delivering, Anti-HIV-1 FANA Oligonucleotides as a Potential New Approach to HIV Therapy. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 615-625.	2.3	33
22	Aptamer-Targeted RNAi for HIV-1 Therapy. <i>Methods in Molecular Biology</i> , 2011, 721, 355-371.	0.4	33
23	Therapeutic Potential of Aptamer-siRNA Conjugates for Treatment of HIV-1. <i>BioDrugs</i> , 2012, 26, 393-400.	2.2	32
24	Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery. <i>Journal of Visualized Experiments</i> , 2011, , .	0.2	31
25	Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells. <i>Nature Protocols</i> , 2021, 16, 327-351.	5.5	30
26	Progress in RNAi-Based Antiviral Therapeutics. <i>Methods in Molecular Biology</i> , 2011, 721, 67-75.	0.4	29
27	Cell-Type-Specific Aptamer and Aptamer-Small Interfering RNA Conjugates for Targeted Human Immunodeficiency Virus Type 1 Therapy. <i>Journal of Investigative Medicine</i> , 2014, 62, 914-919.	0.7	19
28	Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. <i>Journal of Cancer Therapy</i> , 2013, 04, 872-890.	0.1	18
29	Therapeutic Potential of Aptamer-siRNA Conjugates for Treatment of HIV-1. <i>BioDrugs</i> , 2012, 26, 393-400.	2.2	17
30	Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. <i>Molecular Therapy</i> , 2019, 27, 999-1016.	3.7	13
31	Deep Sequencing Analyses of DsiRNAs Reveal the Influence of 3' Terminal Overhangs on Dicing Polarity, Strand Selectivity, and RNA Editing of siRNAs. <i>Molecular Therapy - Nucleic Acids</i> , 2012, 1, e17.	2.3	11
32	Methods for Assembling B-Cell Lymphoma Specific and Internalizing Aptamer-siRNA Nanoparticles Via the Sticky Bridge. <i>Methods in Molecular Biology</i> , 2015, 1297, 169-185.	0.4	8
33	Humanized NOD/SCID/IL2r α ^{-/-} (hu-NSG) Mouse Model for HIV Replication and Latency Studies. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	7
34	Tissue-Specific Delivery of Oligonucleotides. <i>Methods in Molecular Biology</i> , 2019, 2036, 17-50.	0.4	6
35	Evolution of Cell-Type-Specific RNA Aptamers Via Live Cell-Based SELEX. <i>Methods in Molecular Biology</i> , 2016, 1421, 191-214.	0.4	5
36	siRNA Delivery: Mastering Dendrimer Self-Assembly for Efficient siRNA Delivery: From Conceptual Design to In Vivo Efficient Gene Silencing (<i>Small</i> 27/2016). <i>Small</i> , 2016, 12, 3604-3604.	5.2	3